SCHEMBL3889916

SCHEMBL3889916

COc1cc(O)cc(O)c1C(=O)C=Cc1ccc(O)c(OCC=C(C)C)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.65
KMT2A Q03164 4/20 0.65
TDP1 Q9NUW8 4/20 0.65
MAPT P10636 3/20 0.65
KDM4E B2RXH2 2/20 0.65
CYP3A4 P08684 2/20 0.65
HPGD P15428 2/20 0.65
MCL1 Q07820 1/20 0.65
PTGES O14684 6/20 0.63
KCNA3 P22001 1/20 0.61
NPSR1 Q6W5P4 1/20 0.61
TP53 P04637 2/20 0.59
MDM2 Q00987 1/20 0.59
ABCG2 Q9UNQ0 2/20 0.58
ALOX5 P09917 2/20 0.57
USP2 O75604 1/20 0.56
ALDH1A1 P00352 1/20 0.56
ALOX15 P16050 1/20 0.56
MAPK1 P28482 1/20 0.56
NFKB1 P19838 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30383163 1.00 MEN1 (0.65) MEN1KMT2ATDP1MAPTKDM4E
SCHEMBL25206745 1.00 MEN1 (0.65) MEN1KMT2ATDP1MAPTKDM4E
SCHEMBL1938672 0.87 MEN1 (0.83) MEN1KMT2ATDP1MAPTKDM4E
SCHEMBL1938668 0.87 MEN1 (0.83) MEN1KMT2ATDP1MAPTKDM4E
SCHEMBL30383894 0.85 ABCG2 (0.72) MEN1KMT2ATDP1MAPTKDM4E
SCHEMBL25206126 0.85 ABCG2 (0.72) MEN1KMT2ATDP1MAPTKDM4E
SCHEMBL25206127 0.85 ABCG2 (0.72) MEN1KMT2ATDP1MAPTKDM4E
SCHEMBL1659323 0.85 CYP19A1 (0.64) MEN1KMT2ATDP1MAPTKDM4E
SCHEMBL31233320 0.85 CYP19A1 (0.64) MEN1KMT2ATDP1MAPTKDM4E
SCHEMBL25191418 0.85 CYP3A4 (0.68) MEN1KMT2ATDP1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
WO-2009026206-A1 METHOD FOR SYNTHESIZING XANTHOHUMOL UNIVERSITY OF TOLEDO (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MEN1 3367/4885KMT2A 2792/4885TDP1 3071/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 MEN1 2457/4885KMT2A 3188/4885TDP1 3151/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MEN1 2457/4885KMT2A 3188/4885TDP1 3151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.